Press Releases


NEWS


Renalytix Reports Full Year Fiscal 2021 Results
LONDON and SALT LAKE CITY, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based
10.21.21



Renalytix to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results on October 21
LONDON and SALT LAKE CITY, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release fourth quarter and full year fiscal 2021 financial results on Thursday, October 21, 2021, before market open.
10.08.21



Renalytix Launching KidneyIntelX in Veterans Health Administration Hospitals
Jed Fulk Appointed Vice President Sales, Government Accounts NEW YORK and SALT LAKE CITY, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the expansion of its commercial strategy to address early-stage kidney disease in the Veterans Health Administration
10.07.21



Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX™ Enabled Health Care Model
Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021 NEW YORK and SALT LAKE CITY, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) and the Mount Sinai Health System today announced scaled-up implementation of the KidneyIntelX™
09.14.21



Renalytix to Present at the 2021 Wells Fargo Virtual Healthcare Conference
NEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 2021 Wells Fargo Virtual Healthcare Conference. Renalytix’s management is scheduled to participate
09.03.21



Renalytix Appoints Daniel J. Levangie to its Board of Directors
Levangie brings extensive commercial operating experience to Renalytix, served on boards of Exact Sciences, Insulet Corporation and Hologic NEW YORK and SALT LAKE CITY, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Daniel J.
08.30.21



Payer Budget Impact Analysis Projects Significant Savings from KidneyIntelX™ Testing at Primary Care Level
Peer reviewed publication in Journal of Medical Economics supports payer coverage for early-stage risk assessment and care management in the primary care office NEW YORK and SALT LAKE CITY, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the publication of
08.26.21



Renalytix Appoints Ann Berman to its Board of Directors
Berman serves on the board of Loews Corporation, is a member of the board of trustees of Beth Israel Deaconess, and is a former chief financial officer of Harvard University NEW YORK and SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the
07.28.21



Renalytix to Present at the 41st Annual Canaccord Genuity Global Growth Conference
NEW YORK, July 26, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 41 st Annual Canaccord Genuity Virtual Global Growth Conference. Renalytix’s management is scheduled to present at the
07.26.21



Renalytix Appoints Joseph Hutson Vice President of Global Quality and Regulatory
Hutson to Build on Renalytix Quality and Regulatory Strategy for KidneyIntelX Global Commercialization NEW YORK and SALT LAKE CITY, July 22, 2021 (GLOBE NEWSWIRE) -- Renalytix Plc (NASDAQ: RNLX) (LSE: RENX) today announced the appointment of Joseph Hutson as its Vice President of Quality and
07.22.21